A Phase 1 interventional study of Co-administration of 50 mg sitagliptin and 500 mg metformin and sitagliptin/metformin 50 mg/500 mg tablet in Type 2 Diabetes, sponsored by Merck Sharp & Dohme LLC. Completed. Open to male participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-07-28.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 152nd largest by enrollment of the 197 interventional ones that give a count, is one of 23 that started in 2010, is one of 23 in phase 1, and was the 85th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Beijing Chao Yang Hospital · Sites in China
Ages 18–65
Bahria University · Sites in Pakistan
Ages 30–55
Yonsei University · Sites in Korea, Republic of
Ages 19–75
By country, each count listing its studies:
sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 40 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
198 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 11 · Phase 3 74 · Phase 4 68
First in 2003; this study’s year is marked. 23 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 28 is below the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 102 across the 197 interventional studies. Of the 172 that completed or were terminated, 117 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
103 of 198 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 181 finished, 150 (83%) have results posted.
Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 137th largest by enrollment of the 170 interventional ones that give a count, is one of 16 that started in 2010, is one of 55 in phase 1, and was the 102nd registered.
Merck & Co., Inc’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 181 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will test the hypothesis that the Final Market Image (FMI) sitagliptin/metformin 50 mg/500 mg and 50 mg/850 mg (Fixed Dose Combination) FDC tablet and co-administration of corresponding doses of sitagliptin and China-sourced metformin as individual tablets will be bioequivalent based on assessment of the AUC(0-t) and Cmax, for both sitagliptin and metformin.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants were administered treatment in the following sequence with a minimum 7 day washout period between treatments: * Co-administration of 50 mg sitagliptin and 500 mg metformin * sitagliptin/metformin 50 mg/500 mg FDC tablet * sitagliptin/metformin 50 mg/850 mg FDC tablet * Co-administration of 50 mg sitagliptin and 850 mg metformin
Drug: Co-administration of 50 mg sitagliptin and 500 mg metformin · Drug: sitagliptin/metformin 50 mg/500 mg tablet · Drug: Co-administration of 50 mg sitagliptin and 850 mg metformin · Drug: sitagliptin/metformin 50 mg/850 mg tablet
Participants were administered treatment in the following sequence with a minimum 7 day washout period between treatments: * sitagliptin/metformin 50 mg/500 mg FDC tablet * Co-administration of 50 mg sitagliptin and 850 mg metformin * Co-administration of 50 mg sitagliptin and 500mg metformin * sitagliptin/metformin 50 mg/850 mg FDC tablet
Drug: Co-administration of 50 mg sitagliptin and 500 mg metformin · Drug: sitagliptin/metformin 50 mg/500 mg tablet · Drug: Co-administration of 50 mg sitagliptin and 850 mg metformin · Drug: sitagliptin/metformin 50 mg/850 mg tablet
Participants were administered treatment in the following sequence with a minimum 7 day washout period between treatments: * Co-administration of 50 mg sitagliptin and 850 mg metformin * sitagliptin/metformin 50 mg/850 mg FDC tablet * sitagliptin/metformin 50 mg/500 mg FDC tablet * Co-administration of 50 mg sitagliptin and 500mg metformin
Drug: Co-administration of 50 mg sitagliptin and 500 mg metformin · Drug: sitagliptin/metformin 50 mg/500 mg tablet · Drug: Co-administration of 50 mg sitagliptin and 850 mg metformin · Drug: sitagliptin/metformin 50 mg/850 mg tablet
Participants were administered treatment in the following sequence with a minimum 7 day washout period between treatments: * sitagliptin/metformin 50 mg/850 mg FDC tablet * Co-administration of 50 mg sitagliptin and 500 mg metformin * Co-administration of 50 mg sitagliptin and 850 mg metformin * sitagliptin/metformin 50 mg/500 mg FDC tablet
Drug: Co-administration of 50 mg sitagliptin and 500 mg metformin · Drug: sitagliptin/metformin 50 mg/500 mg tablet · Drug: Co-administration of 50 mg sitagliptin and 850 mg metformin · Drug: sitagliptin/metformin 50 mg/850 mg tablet
Drug pages: Sitagliptin · Metformin
Co-administration of 50 mg sitagliptin and 500 mg China-sourced metformin as individual tablets with 240 ml water on Day 1 of the relevant treatment period (Sit + Met500) after fasting for at least 10 hours.
Drug pages: Sitagliptin · Metformin
Single dose administration of the final marketing image (FMI) sitagliptin/metformin 50 mg/500 mg fixed-dose combination (FDC) tablet with 240 ml water on Day 1 of the relevant treatment period (SitMet850 FDC) after fasting for at least 10 hours.
Drug pages: Sitagliptin · Metformin
Co-administration of 50 mg sitagliptin and 850 mg China sourced metformin as individual tablets with 240 ml water on Day 1 of the relevant treatment period (Sit + Met850) after fasting for at least 10 hours.
Drug pages: Sitagliptin · Metformin
Single dose administration of the FMI sitagliptin/metformin 50 mg/850 mg FDC tablet with 240 ml water on Day 1 of the relevant treatment period (SitMet850 FDC) after fasting for at least 10 hours.
Area Under the Curve (AUC(0-t)) for Sitagliptin
AUC (0-t) is the area under the curve for the plot showing plasma concentration against time from time zero to the time of the last quantifiable concentration for sitagliptin 50 mg, metformin 500 mg and metformin 850 mg.
Time frame: baseline through 72 hours postdose
Cmax for Sitagliptin and Metformin
Cmax is the peak serum concentration of a therapeutic drug after administration; and is used to determine the rate and extent of drug absorption. Cmax is reported for sitagliptin 50 mg, metformin 500 mg and metformin 850 mg.
Time frame: baseline through 72 hours postdose
28 participants were randomized in four treatment sequences. Participants had a 7 day minimum washout period between treatments.
| Milestone | 1. Sit + Met500 / SitMet500 FDC / SitMet850 FDC / Sit + Met850 | 2. SitMet500 FDC / Sit + Met850 / Sit + Met500 / SitMet850 FDC | 3. Sit + Met850 / SitMet850 FDC / SitMet500 FDC / Sit + Met500 | 4. SitMet850 FDC / Sit + Met500 / Sit + Met850 / SitMet500 FDC |
|---|---|---|---|---|
| Started | 7 | 7 | 7 | 7 |
| Completed | 7 | 7 | 7 | 7 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | 1. Sit + Met500 / SitMet500 FDC / SitMet850 FDC / Sit + Met850 | 2. SitMet500 FDC / Sit + Met850 / Sit + Met500 / SitMet850 FDC | 3. Sit + Met850 / SitMet850 FDC / SitMet500 FDC / Sit + Met500 | 4. SitMet850 FDC / Sit + Met500 / Sit + Met850 / SitMet500 FDC |
|---|---|---|---|---|
| Started | 7 | 7 | 6 | 7 |
| Completed | 7 | 7 | 6 | 7 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | 1. Sit + Met500 / SitMet500 FDC / SitMet850 FDC / Sit + Met850 | 2. SitMet500 FDC / Sit + Met850 / Sit + Met500 / SitMet850 FDC | 3. Sit + Met850 / SitMet850 FDC / SitMet500 FDC / Sit + Met500 | 4. SitMet850 FDC / Sit + Met500 / Sit + Met850 / SitMet500 FDC |
|---|---|---|---|---|
| Started | 7 | 7 | 6 | 7 |
| Completed | 7 | 7 | 6 | 7 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | 1. Sit + Met500 / SitMet500 FDC / SitMet850 FDC / Sit + Met850 | 2. SitMet500 FDC / Sit + Met850 / Sit + Met500 / SitMet850 FDC | 3. Sit + Met850 / SitMet850 FDC / SitMet500 FDC / Sit + Met500 | 4. SitMet850 FDC / Sit + Met500 / Sit + Met850 / SitMet500 FDC |
|---|---|---|---|---|
| Started | 7 | 7 | 6 | 7 |
| Completed | 7 | 7 | 6 | 7 |
| Not completed | 0 | 0 | 0 | 0 |
AUC (0-t) is the area under the curve for the plot showing plasma concentration against time from time zero to the time of the last quantifiable concentration for sitagliptin 50 mg, metformin 500 mg and metformin 850 mg.
| hr*ng/mL | Sit 50 mg + Met 500 mg | SitMet 50mg/500mg FDC | Sit 50 mg + Met 850 mg | SitMet 50mg/850mg FDC |
|---|---|---|---|---|
| sitagliptin 50 mg | 1570 ± 217.40 | 1590 ± 186.58 | 1520 ± 228.83 | 1600 ± 195.05 |
| metformin 500 mg | 8350 ± 1881.70 | 8750 ± 1920.45 | NA ± NA | NA ± NA |
| metformin 850 mg | NA ± NA | NA ± NA | 11800 ± 2849.36 | 13100 ± 2987.28 |
Cmax is the peak serum concentration of a therapeutic drug after administration; and is used to determine the rate and extent of drug absorption. Cmax is reported for sitagliptin 50 mg, metformin 500 mg and metformin 850 mg.
| ng/mL | Sit 50 mg + Met 500 mg | SitMet 50mg/500mg FDC | Sit 50 mg + Met 850 mg | SitMet 50mg/850mg FDC |
|---|---|---|---|---|
| sitagliptin 50 mg | 189 ± 37.76 | 182 ± 38.71 | 187 ± 40.31 | 194 ± 32.67 |
| Metformin 500 mg | 1210 ± 323.83 | 1310 ± 383.57 | NA ± NA | NA ± NA |
| Metformin 850 mg | NA ± NA | NA ± NA | 1790 ± 488.51 | 1970 ± 482.69 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sit 50 mg + Met 500 mg | — | 0/28 (0%) | 4/28 (14.3%) |
| Sit/Met 50 mg/500 mg FDC | — | 0/28 (0%) | 3/28 (10.7%) |
| Sit 50 mg + Met 850 mg | — | 0/28 (0%) | 4/28 (14.3%) |
| Sit/Met 50 mg/850 mg FDC | — | 0/28 (0%) | 2/28 (7.1%) |
| Event | Sit 50 mg + Met 500 mg | Sit/Met 50 mg/500 mg FDC | Sit 50 mg + Met 850 mg | Sit/Met 50 mg/850 mg FDC |
|---|---|---|---|---|
| DiarrheaGastrointestinal disorders | 2/28 | 1/28 | 1/28 | 0/28 |
| FlatulenceGastrointestinal disorders | 0/28 | 0/28 | 2/28 | 0/28 |
| HeadacheNervous system disorders | 1/28 | 0/28 | 0/28 | 0/28 |
| Abdominal painGastrointestinal disorders | 1/28 | 1/28 | 1/28 | 1/28 |
| FeverGeneral disorders | 1/28 | 0/28 | 0/28 | 0/28 |
| VertigoEar and labyrinth disorders | 1/28 | 0/28 | 0/28 | 0/28 |
| NauseaGastrointestinal disorders | 1/28 | 1/28 | 0/28 | 0/28 |
| Chest painGeneral disorders | 0/28 | 0/28 | 1/28 | 0/28 |
| RashSkin and subcutaneous tissue disorders | 0/28 | 0/28 | 1/28 | 0/28 |
| LeucocytosisBlood and lymphatic system disorders | 0/28 | 0/28 | 0/28 | 1/28 |
| Age, Continuous(years) | All Participants |
|---|---|
| Mean | 28.6 ± 5.61 |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 0 |
| Male | 28 |
| Region of Enrollment(participants) | All Participants |
|---|---|
| China | 28 |
| Body Mass Index (BMI)(kg/m^2) | All Participants |
|---|---|
| Mean | 22 ± 1.22 |
No study locations are listed for this record.
The record gives a start of Apr 2010, a primary completion of Jun 2010 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2011, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Sitagliptin · Metformin